Get More Information on Vagus Nerve Stimulation Market - Request Sample Report
The Vagus Nerve Stimulation Market Size was valued at USD 456.88 Million in 2023, and is expected to reach USD 1,074.62 Million by 2032, and grow at a CAGR of 10.48% over the forecast period 2024-2032.
The market for neurostimulation devices is increasing, which also led to finding a better class that has minimal side effects and thus is optimal therapy. Neurological conditions account for 4.5%-11% of all illnesses as estimated by the WHO, in low or high-income countries alike This figure is greater than that of respiratory diseases, gastrointestinal problems, or certain cancers, and further, his burden will probably experience a rise in the future years. The US has also seen a substantial rise in neurological disorders, and this trend is expected to persist for the next twenty years. Neurological disorders account for a mean of 3200 per 100,000 population and range between approximately as low as only about half this average to twice the (~2–6 in every thousand) prevalence. A common neurological disorder, epilepsy affects millions of people worldwide. This disease is, in most of the populated countries on Earth like India and China. Due to this increasing incidence, the demand for numerous devices and therapies has been on an ever increase like Vagal nerve stimulation (VNS). The therapeutic use of vagal nerve stimulation is expanding, according to Jacobs. It is used in the treatment of neurological diseases such as epilepsy, depression, and other clinical applications. As such, VNS is expected to be part of the treatment for neurological diseases on a global scale.
MARKET DYNAMICS:
KEY DRIVERS:
Increasing Incidences of Neurological Diseases Such as Migraine and Epilepsy Leading to Demand for Vagus Nerve Stimulation Products Boost Market Growth.
Growing Acceptance of Neuromodulation Therapies is Responsible for the Growth of the Vagus Nerve Stimulation Products Market.
RESTRAINTS:
Regulatory Frameworks Often Face Significant Challenges, Such as Bureaucratic Delays, Complex Approval Processes, And Resistance from Industry Stakeholders Impeding the Growth of the Market.
Alternative Therapies, Such as Herbal Remedies and Non-Conventional Treatments, Can Compete with Established Medical Treatments.
OPPORTUNITY:
The Development of Innovative VNS Devices, Such as Minimally Invasive and Non-Invasive Stimulation Techniques, is Expanding the Market Growth.
The Establishment of Favorable Reimbursement Policies in Various Countries is Providing Lucrative Growth Opportunities for The Market
By Product
In 2023, the implantable VNS device segment led in terms of revenue contribution with over a 60% share of this market due growing number of headache, depression, and epilepsy patients across the globe The VNS devices implanted are designed specifically to target the pain site and work by modulating nerve activity through sending an electric stimulation in a particular nerve making it a promising treatment method for this disease. Vagus Nerve Stimulation Market - Based on the product, the vagus nerve stimulation market is divided into implantable and external VNS devices. For people who have not responded to anti-seizure drugs and other intensive depression treatments, such as antidepressant medications, psychotherapy, or electroconvulsive therapy (ECT), an implantable VNS device can be a lifesaver. The launch of novel VNS devices by leading market participants further supports the widespread acceptance and demand for these devices in global markets. For example, MicroTransponder received FDA approval in August 2021 for the Vivistim Paired VNS System which is indicated to treat moderate-to-severe upper extremity motor deficits resulting from chronic ischemic stroke.
Nevertheless, the percentage share of external VNS devices is likely to soar at a CAGR Of 12% between 2024 To 2032. It is mainly due to the growth of patients suffering from chronic diseases and increasing preference for non-invasive treatment as well as cost-effectiveness. Developing new devices, patent pushing towards non-invasive devices changing the patient preference for advanced testing techniques over conventional surgical methods will increase the demand. Adverse events related to implantable VNS devices can span from surgical procedures itself electrical stimulation. As a consequence, non-invasive VNS (nVNS) devices were designed to eliminate the disadvantages associated with implants. Some examples of the non-invasive vagus nerve stimulators that are commercially available include gammaCore Sapphire by electroCore, and Parasym device by Parasym Ltd.
Need any customization research on Vagus Nerve Stimulation Markett - Enquiry Now
By Application
The epilepsy segment dominated the market in 2023, contributing a revenue share of 59% due to rising regulatory approvals and global prevalence rate for epilepsy violence around world-wide for instance, according to the WHO epilepsy is diagnosed in high-income countries with 49 out of 100.000 inhabitants per year and by comparison in low- middle-income countries there are register about 139 people. Additionally, about 100-120 thousand children with epilepsy are hospitalized annually in the United States (US) with associated conditions. This is anticipated to skyrocket the growth of the market. Further, continuous rise in the awareness levels concerning epilepsy treatment together with strategic partnerships are projected to bolster market growth. This has created awareness among the population leading to the higher need for proper diagnoses and treatment in a significant percentage through epilepsy networks. For example, international inauguration; The Epilepsy Association of Nova Scotia joined forces with the Anita Kaufmann Foundation to announce that March 26 was now” Purple Day” internationally and a day for epilepsy specifically.
Medications that are used to treat depression, can be selective serotonin reuptake inhibitors or tricyclic antidepressants. These medications change your chemistry, and have different side effects in different people We all know how the proportion of stress and depression is scaling up on a usual basis throughout the globe. More than 2.7 million American adults carry the weight of treatment-resistant depression, as defined by the National Institute of Mental Health (NIHM). Moreover, According to WHO, more than 300 million adults are facing depression around the world and one-third of patients with major depressive disorder (MDD) have failed treatment-resistant depression (TRD).
By Biomaterial
The metallic biomaterials segment led the market with a 50% revenue share in 2023, owing to the increased R&D for these therapies’ advancements along with the growth of technologies under this application space. The segment will also hold its ground through 2032. Metallic biomaterials: These are commonly used as medical devices and implantable components that give the material its thermal conductivity & mechanical properties. Metals such as 316L stainless steel, titanium-based alloys, gold tantalum, and silver are chosen for the encapsulation of electrical implantable devices due to their capacity to reduce inflammation affecting their conductivity. The polymeric segment is projected to expand at the fastest CAGR of 11%. Depression and stress are on the rise across multiple countries besides ours. Polymers, (such as electro-spun matrices and neural conduits/scaffolds) are being developed to serve as support structures that can regenerate damaged neural tissues.
REGIONAL ANALYSIS:
Due to the rise in government funding and initiatives for increasing awareness of epilepsy, stubborn depression, etc., North America accounted for approximately 60% share by revenue based on geography owning the largest shares from the Vagus Nerve Stimulation market. Moreover, the high growth in technological advancements, availability of key manufacturing and R&D hubs in this region with a rise of governmental funding & initiatives are a few drivers that fuel the overall growth of the market. According to CMS - the Centers for Medicare & Medicaid Services, health spending in the U.S. is expected to grow at 5.5% each year from 2018 through its forecast period until ten years later (2027) and reach USD 6 trillion by that final target milestone reached the end of this forthcoming decade (Appendix). Also, high income in developed economies and several qualified professionals are some of the strong factors responsible for North America dominating the market.
The Asia Pacific region is projected to grow at a faster rate. This can be ascribed to the increasing incidence of neurodegenerative diseases in this region and the increased need for innovative solutions that are capable of delivering long-term results. Increasing awareness about treatment options available for neurological diseases and the development of clinical trial infrastructures in emerging APAC countries are expected to register the fastest growth over the forecast period. Further, increasing the number of developing countries like Japan, China, and India would also contribute to positive market growth in high-growth regions. Likewise, the establishment of organizations like the Asia-Pacific Centre for Neuromodulation (APCN) to focus on studies related to VNS benefits is also anticipated to create a high influence on noting growth rates in the region.
The key market players include SetPoint Medical Corporation, MicroTransponder Inc., Soterix Medical Inc., Thermo Fisher Scientific, Parasym Ltd., ElectroCore, Inc., Neuropix Company Ltd., TVNS Health GmbH, Beijing PINS Medical Co., Ltd., LivaNova PLC. and other players.
In December 2020 ElectroCore, Inc., an established bioelectronic company announced the launch of a new consumer wellness line called Truvaga for patients in the United States.
In 2023 SenTiva DUO, is a VNS Therapy solution that is compatible with the implantable pulse generator (IPG) with dual pin header option market-leading medical technology and innovation business LivaNova PLC.
| Report Attributes | Details |
|
Market Size in 2023 |
US$ 456.88 Million |
|
Market Size by 2032 |
US$ 1,074.62 Million |
|
CAGR |
CAGR of 10.48% From 2024 to 2032 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2032 |
|
Historical Data |
2020-2022 |
|
Report Scope & Coverage |
Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
|
Key Segments |
•By Product (Implantable VNS Device, External VNS Device) |
|
Regional Analysis/Coverage |
North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
|
Company Profiles |
Thermo Fisher Scientific, MicroTransponder Inc., Neuropix Company Ltd., Soterix Medical Inc., SetPoint Medical Corporation, Parasym Ltd., ElectroCore, Inc., TVNS Health GmbH, Beijing PINS Medical Co., Ltd., LivaNova PLC. and other players |
|
Key Drivers |
•Increasing Incidences of Neurological Diseases Such as Migraine and Epilepsy Leading to Demand for Vagus Nerve Stimulation Products Boost Market Growth. |
|
RESTRAINTS |
•Regulatory Frameworks Often Face Significant Challenges, Such as Bureaucratic Delays, Complex Approval Processes, And Resistance from Industry Stakeholders Impeding the Growth of the Market. |
Ans: The U.S. led the Vagus Nerve Stimulation in the North American region with the highest revenue share in 2023.
Ans: Factors such as regulatory frameworks often face significant challenges, such as bureaucratic delays, complex approval processes, and resistance from industry stakeholders impeding the growth of the market as well as alternative therapies, such as herbal remedies and non-conventional treatments, can compete with established medical treatments can impact the development of Vagus Nerve Stimulation.
Ans The implantable VNS device held the largest share in the Vagus Nerve Stimulation Market in 2023.
Ans: The expected CAGR of the Global Vagus Nerve Stimulation Market during the forecast period is 10.48%.
Ans: The Vagus Nerve Stimulation Market was valued at USD 456.88 Million in 2023.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Porter’s 5 Forces Model
6. Pest Analysis
7. Vagus Nerve Stimulation Market Segmentation, By Product
7.1 Introduction
7.2 Implantable VNS Device
7.3 External VNS Device
8. Vagus Nerve Stimulation Market Segmentation, By Application
8.1 Introduction
8.2 Epilepsy
8.3 Migraine
8.4 Depression
9. Vagus Nerve Stimulation Market Segmentation, By Biomaterial
9.1 Introduction
9.2 Metallic
9.3 Ceramics
9.4 Polymeric
10. Vagus Nerve Stimulation Market Segmentation, By End-Use
10.1 Introduction
10.2 Hospitals
10.3 Neurology Clinics
10.4 Ambulatory Surgical Centers
10.5 Research Centers
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 Trend Analysis
11.2.2 North America Vagus Nerve Stimulation Market by Country
11.2.3 North America Vagus Nerve Stimulation Market By Product
11.2.4 North America Vagus Nerve Stimulation Market By Application
11.2.5 North America Vagus Nerve Stimulation Market By Biomaterial
11.2.6 North America Vagus Nerve Stimulation Market By End-Use
11.2.7 USA
11.2.7.1 USA Vagus Nerve Stimulation Market By Product
11.2.7.2 USA Vagus Nerve Stimulation Market By Application
11.2.7.3 USA Vagus Nerve Stimulation Market By Biomaterial
11.2.7.4 USA Vagus Nerve Stimulation Market By End-Use
11.2.8 Canada
11.2.8.1 Canada Vagus Nerve Stimulation Market By Product
11.2.8.2 Canada Vagus Nerve Stimulation Market By Application
11.2.8.3 Canada Vagus Nerve Stimulation Market By Biomaterial
11.2.8.4 Canada Vagus Nerve Stimulation Market By End-Use
11.2.9 Mexico
11.2.9.1 Mexico Vagus Nerve Stimulation Market By Product
11.2.9.2 Mexico Vagus Nerve Stimulation Market By Application
11.2.9.3 Mexico Vagus Nerve Stimulation Market By Biomaterial
11.2.9.4 Mexico Vagus Nerve Stimulation Market By End-Use
11.3 Europe
11.3.1 Trend Analysis
11.3.2 Eastern Europe
11.3.2.1 Eastern Europe Vagus Nerve Stimulation Market by Country
11.3.2.2 Eastern Europe Vagus Nerve Stimulation Market By Product
11.3.2.3 Eastern Europe Vagus Nerve Stimulation Market By Application
11.3.2.4 Eastern Europe Vagus Nerve Stimulation Market By Biomaterial
11.3.2.5 Eastern Europe Vagus Nerve Stimulation Market By End-Use
11.3.2.6 Poland
11.3.2.6.1 Poland Vagus Nerve Stimulation Market By Product
11.3.2.6.2 Poland Vagus Nerve Stimulation Market By Application
11.3.2.6.3 Poland Vagus Nerve Stimulation Market By Biomaterial
11.3.2.6.4 Poland Vagus Nerve Stimulation Market By End-Use
11.3.2.7 Romania
11.3.2.7.1 Romania Vagus Nerve Stimulation Market By Product
11.3.2.7.2 Romania Vagus Nerve Stimulation Market By Application
11.3.2.7.3 Romania Vagus Nerve Stimulation Market By Biomaterial
11.3.2.7.4 Romania Vagus Nerve Stimulation Market By End-Use
11.3.2.8 Hungary
11.3.2.8.1 Hungary Vagus Nerve Stimulation Market By Product
11.3.2.8.2 Hungary Vagus Nerve Stimulation Market By Application
11.3.2.8.3 Hungary Vagus Nerve Stimulation Market By Biomaterial
11.3.2.8.4 Hungary Vagus Nerve Stimulation Market By End-Use
11.3.2.9 Turkey
11.3.2.9.1 Turkey Vagus Nerve Stimulation Market By Product
11.3.2.9.2 Turkey Vagus Nerve Stimulation Market By Application
11.3.2.9.3 Turkey Vagus Nerve Stimulation Market By Biomaterial
11.3.2.9.4 Turkey Vagus Nerve Stimulation Market By End-Use
11.3.2.10 Rest of Eastern Europe
11.3.2.10.1 Rest of Eastern Europe Vagus Nerve Stimulation Market By Product
11.3.2.10.2 Rest of Eastern Europe Vagus Nerve Stimulation Market By Application
11.3.2.10.3 Rest of Eastern Europe Vagus Nerve Stimulation Market By Biomaterial
11.3.2.10.4 Rest of Eastern Europe Vagus Nerve Stimulation Market By End-Use
11.3.3 Western Europe
11.3.3.1 Western Europe Vagus Nerve Stimulation Market by Country
11.3.3.2 Western Europe Vagus Nerve Stimulation Market By Product
11.3.3.3 Western Europe Vagus Nerve Stimulation Market By Application
11.3.3.4 Western Europe Vagus Nerve Stimulation Market By Biomaterial
11.3.3.5 Western Europe Vagus Nerve Stimulation Market By End-Use
11.3.3.6 Germany
11.3.3.6.1 Germany Vagus Nerve Stimulation Market By Product
11.3.3.6.2 Germany Vagus Nerve Stimulation Market By Application
11.3.3.6.3 Germany Vagus Nerve Stimulation Market By Biomaterial
11.3.3.6.4 Germany Vagus Nerve Stimulation Market By End-Use
11.3.3.7 France
11.3.3.7.1 France Vagus Nerve Stimulation Market By Product
11.3.3.7.2 France Vagus Nerve Stimulation Market By Application
11.3.3.7.3 France Vagus Nerve Stimulation Market By Biomaterial
11.3.3.7.4 France Vagus Nerve Stimulation Market By End-Use
11.3.3.8 UK
11.3.3.8.1 UK Vagus Nerve Stimulation Market By Product
11.3.3.8.2 UK Vagus Nerve Stimulation Market By Application
11.3.3.8.3 UK Vagus Nerve Stimulation Market By Biomaterial
11.3.3.8.4 UK Vagus Nerve Stimulation Market By End-Use
11.3.3.9 Italy
11.3.3.9.1 Italy Vagus Nerve Stimulation Market By Product
11.3.3.9.2 Italy Vagus Nerve Stimulation Market By Application
11.3.3.9.3 Italy Vagus Nerve Stimulation Market By Biomaterial
11.3.3.9.4 Italy Vagus Nerve Stimulation Market By End-Use
11.3.3.10 Spain
11.3.3.10.1 Spain Vagus Nerve Stimulation Market By Product
11.3.3.10.2 Spain Vagus Nerve Stimulation Market By Application
11.3.3.10.3 Spain Vagus Nerve Stimulation Market By Biomaterial
11.3.3.10.4 Spain Vagus Nerve Stimulation Market By End-Use
11.3.3.11 Netherlands
11.3.3.11.1 Netherlands Vagus Nerve Stimulation Market By Product
11.3.3.11.2 Netherlands Vagus Nerve Stimulation Market By Application
11.3.3.11.3 Netherlands Vagus Nerve Stimulation Market By Biomaterial
11.3.3.11.4 Netherlands Vagus Nerve Stimulation Market By End-Use
11.3.3.12 Switzerland
11.3.3.12.1 Switzerland Vagus Nerve Stimulation Market By Product
11.3.3.12.2 Switzerland Vagus Nerve Stimulation Market By Application
11.3.3.12.3 Switzerland Vagus Nerve Stimulation Market By Biomaterial
11.3.3.12.4 Switzerland Vagus Nerve Stimulation Market By End-Use
11.3.3.13 Austria
11.3.3.13.1 Austria Vagus Nerve Stimulation Market By Product
11.3.3.13.2 Austria Vagus Nerve Stimulation Market By Application
11.3.3.13.3 Austria Vagus Nerve Stimulation Market By Biomaterial
11.3.3.13.4 Austria Vagus Nerve Stimulation Market By End-Use
11.3.3.14 Rest of Western Europe
11.3.3.14.1 Rest of Western Europe Vagus Nerve Stimulation Market By Product
11.3.3.14.2 Rest of Western Europe Vagus Nerve Stimulation Market By Application
11.3.3.14.3 Rest of Western Europe Vagus Nerve Stimulation Market By Biomaterial
11.3.3.14.4 Rest of Western Europe Vagus Nerve Stimulation Market By End-Use
11.4 Asia-Pacific
11.4.1 Trend Analysis
11.4.2 Asia-Pacific Vagus Nerve Stimulation Market by Country
11.4.3 Asia-Pacific Vagus Nerve Stimulation Market By Product
11.4.4 Asia-Pacific Vagus Nerve Stimulation Market By Application
11.4.5 Asia-Pacific Vagus Nerve Stimulation Market By Biomaterial
11.4.6 Asia-Pacific Vagus Nerve Stimulation Market By End-Use
11.4.7 China
11.4.7.1 China Vagus Nerve Stimulation Market By Product
11.4.7.2 China Vagus Nerve Stimulation Market By Application
11.4.7.3 China Vagus Nerve Stimulation Market By Biomaterial
11.4.7.4 China Vagus Nerve Stimulation Market By End-Use
11.4.8 India
11.4.8.1 India Vagus Nerve Stimulation Market By Product
11.4.8.2 India Vagus Nerve Stimulation Market By Application
11.4.8.3 India Vagus Nerve Stimulation Market By Biomaterial
11.4.8.4 India Vagus Nerve Stimulation Market By End-Use
11.4.9 Japan
11.4.9.1 Japan Vagus Nerve Stimulation Market By Product
11.4.9.2 Japan Vagus Nerve Stimulation Market By Application
11.4.9.3 Japan Vagus Nerve Stimulation Market By Biomaterial
11.4.9.4 Japan Vagus Nerve Stimulation Market By End-Use
11.4.10 South Korea
11.4.10.1 South Korea Vagus Nerve Stimulation Market By Product
11.4.10.2 South Korea Vagus Nerve Stimulation Market By Application
11.4.10.3 South Korea Vagus Nerve Stimulation Market By Biomaterial
11.4.10.4 South Korea Vagus Nerve Stimulation Market By End-Use
11.4.11 Vietnam
11.4.11.1 Vietnam Vagus Nerve Stimulation Market By Product
11.4.11.2 Vietnam Vagus Nerve Stimulation Market By Application
11.4.11.3 Vietnam Vagus Nerve Stimulation Market By Biomaterial
11.4.11.4 Vietnam Vagus Nerve Stimulation Market By End-Use
11.4.12 Singapore
11.4.12.1 Singapore Vagus Nerve Stimulation Market By Product
11.4.12.2 Singapore Vagus Nerve Stimulation Market By Application
11.4.12.3 Singapore Vagus Nerve Stimulation Market By Biomaterial
11.4.12.4 Singapore Vagus Nerve Stimulation Market By End-Use
11.4.13 Australia
11.4.13.1 Australia Vagus Nerve Stimulation Market By Product
11.4.13.2 Australia Vagus Nerve Stimulation Market By Application
11.4.13.3 Australia Vagus Nerve Stimulation Market By Biomaterial
11.4.13.4 Australia Vagus Nerve Stimulation Market By End-Use
11.4.14 Rest of Asia-Pacific
11.4.14.1 Rest of Asia-Pacific Vagus Nerve Stimulation Market By Product
11.4.14.2 Rest of Asia-Pacific Vagus Nerve Stimulation Market By Application
11.4.14.3 Rest of Asia-Pacific Vagus Nerve Stimulation Market By Biomaterial
11.4.14.4 Rest of Asia-Pacific Vagus Nerve Stimulation Market By End-Use
11.5 Middle East & Africa
11.5.1 Trend Analysis
11.5.2 Middle East
11.5.2.1 Middle East Vagus Nerve Stimulation Market by Country
11.5.2.2 Middle East Vagus Nerve Stimulation Market By Product
11.5.2.3 Middle East Vagus Nerve Stimulation Market By Application
11.5.2.4 Middle East Vagus Nerve Stimulation Market By Biomaterial
11.5.2.5 Middle East Vagus Nerve Stimulation Market By End-Use
11.5.2.6 UAE
11.5.2.6.1 UAE Vagus Nerve Stimulation Market By Product
11.5.2.6.2 UAE Vagus Nerve Stimulation Market By Application
11.5.2.6.3 UAE Vagus Nerve Stimulation Market By Biomaterial
11.5.2.6.4 UAE Vagus Nerve Stimulation Market By End-Use
11.5.2.7 Egypt
11.5.2.7.1 Egypt Vagus Nerve Stimulation Market By Product
11.5.2.7.2 Egypt Vagus Nerve Stimulation Market By Application
11.5.2.7.3 Egypt Vagus Nerve Stimulation Market By Biomaterial
11.5.2.7.4 Egypt Vagus Nerve Stimulation Market By End-Use
11.5.2.8 Saudi Arabia
11.5.2.8.1 Saudi Arabia Vagus Nerve Stimulation Market By Product
11.5.2.8.2 Saudi Arabia Vagus Nerve Stimulation Market By Application
11.5.2.8.3 Saudi Arabia Vagus Nerve Stimulation Market By Biomaterial
11.5.2.8.4 Saudi Arabia Vagus Nerve Stimulation Market By End-Use
11.5.2.9 Qatar
11.5.2.9.1 Qatar Vagus Nerve Stimulation Market By Product
11.5.2.9.2 Qatar Vagus Nerve Stimulation Market By Application
11.5.2.9.3 Qatar Vagus Nerve Stimulation Market By Biomaterial
11.5.2.9.4 Qatar Vagus Nerve Stimulation Market By End-Use
11.5.2.10 Rest of Middle East
11.5.2.10.1 Rest of Middle East Vagus Nerve Stimulation Market By Product
11.5.2.10.2 Rest of Middle East Vagus Nerve Stimulation Market By Application
11.5.2.10.3 Rest of Middle East Vagus Nerve Stimulation Market By Biomaterial
11.5.2.10.4 Rest of Middle East Vagus Nerve Stimulation Market By End-Use
11.5.3 Africa
11.5.3.1 Africa Vagus Nerve Stimulation Market by Country
11.5.3.2 Africa Vagus Nerve Stimulation Market By Product
11.5.3.3 Africa Vagus Nerve Stimulation Market By Application
11.5.3.4 Africa Vagus Nerve Stimulation Market By Biomaterial
11.5.3.5 Africa Vagus Nerve Stimulation Market By End-Use
11.5.3.6 Nigeria
11.5.3.6.1 Nigeria Vagus Nerve Stimulation Market By Product
11.5.3.6.2 Nigeria Vagus Nerve Stimulation Market By Application
11.5.3.6.3 Nigeria Vagus Nerve Stimulation Market By Biomaterial
11.5.3.6.4 Nigeria Vagus Nerve Stimulation Market By End-Use
11.5.3.7 South Africa
11.5.3.7.1 South Africa Vagus Nerve Stimulation Market By Product
11.5.3.7.2 South Africa Vagus Nerve Stimulation Market By Application
11.5.3.7.3 South Africa Vagus Nerve Stimulation Market By Biomaterial
11.5.3.7.4 South Africa Vagus Nerve Stimulation Market By End-Use
11.5.3.8 Rest of Africa
11.5.3.8.1 Rest of Africa Vagus Nerve Stimulation Market By Product
11.5.3.8.2 Rest of Africa Vagus Nerve Stimulation Market By Application
11.5.3.8.3 Rest of Africa Vagus Nerve Stimulation Market By Biomaterial
11.5.3.8.4 Rest of Africa Vagus Nerve Stimulation Market By End-Use
11.6 Latin America
11.6.1 Trend Analysis
11.6.2 Latin America Vagus Nerve Stimulation Market by Country
11.6.3 Latin America Vagus Nerve Stimulation Market By Product
11.6.4 Latin America Vagus Nerve Stimulation Market By Application
11.6.5 Latin America Vagus Nerve Stimulation Market By Biomaterial
11.6.6 Latin America Vagus Nerve Stimulation Market By End-Use
11.6.7 Brazil
11.6.7.1 Brazil Vagus Nerve Stimulation Market By Product
11.6.7.2 Brazil Vagus Nerve Stimulation Market By Application
11.6.7.3 Brazil Vagus Nerve Stimulation Market By Biomaterial
11.6.7.4 Brazil Vagus Nerve Stimulation Market By End-Use
11.6.8 Argentina
11.6.8.1 Argentina Vagus Nerve Stimulation Market By Product
11.6.8.2 Argentina Vagus Nerve Stimulation Market By Application
11.6.8.3 Argentina Vagus Nerve Stimulation Market By Biomaterial
11.6.8.4 Argentina Vagus Nerve Stimulation Market By End-Use
11.6.9 Colombia
11.6.9.1 Colombia Vagus Nerve Stimulation Market By Product
11.6.9.2 Colombia Vagus Nerve Stimulation Market By Application
11.6.9.3 Colombia Vagus Nerve Stimulation Market By Biomaterial
11.6.9.4 Colombia Vagus Nerve Stimulation Market By End-Use
11.6.10 Rest of Latin America
11.6.10.1 Rest of Latin America Vagus Nerve Stimulation Market By Product
11.6.10.2 Rest of Latin America Vagus Nerve Stimulation Market By Application
11.6.10.3 Rest of Latin America Vagus Nerve Stimulation Market By Biomaterial
11.6.10.4 Rest of Latin America Vagus Nerve Stimulation Market By End-Use
12. Company Profiles
12.1 Thermo Fisher Scientific
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 The SNS View
12.2 MicroTransponder Inc.
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 The SNS View
12.3 Neuropix Company Ltd.
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 The SNS View
12.4 Soterix Medical Inc.
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 The SNS View
12.5 SetPoint Medical Corporation
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 The SNS View
12.6 Parasym Ltd.
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 The SNS View
12.7 ElectroCore, Inc.
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 The SNS View
12.8 TVNS Health GmbH
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 The SNS View
12.9 Beijing PINS Medical Co., Ltd.
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 The SNS View
12.10 LivaNova PLC
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
13.3.1 Industry News
13.3.2 Company News
13.3.3 Mergers & Acquisitions
14. Use Case and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Product
Implantable VNS Device
External VNS Device
By Application
Epilepsy
Migraine
Depression
By Biomaterial
Metallic
Ceramics
Polymeric
By End-Use
Hospitals
Neurology Clinics
Ambulatory Surgical Centers
Research Centers
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Platelet Rich Plasma Market size was estimated at USD 628.1 million in 2022 and is expected to reach USD 1948.2 million by 2030 at a CAGR of 15.2% during the forecast period of 2023-2030.
The Proteomics Market size was estimated at USD 25.3 billion in 2022 and is expected to reach USD 70.8 billion by 2030 with a growing CAGR of 13.7% during the forecast period of 2023-2030.
The Airway Disease Treatment Market size was estimated at USD 2107.04 million in 2023 and is expected to reach USD 3233.65 million by 2031 at a CAGR of 5.5% during the forecast period of 2024-2031.
The Clinical Risk Grouping Solutions Market Size was valued at USD 640 million in 2022, and is expected to reach USD 1890 million by 2030, and grow at a CAGR of 14.5% over the forecast period 2023-2030.
The Radiotherapy Market size was estimated at USD 6.79 billion in 2023 and is expected to reach USD 10.19 billion by 2031 at a CAGR of 5.53% during the forecast period of 2024-2031.
The Assisted Reproductive Technology (ART) Market is expected to reach USD 45.75 Bn by 2032 and was valued at USD 27.13 Bn in 2023 the CAGR growth rate will be 5.98% over the forecast period of 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
